4th Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$1,600,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

S. 4574/ HR 8254- Bringing Enhanced Treatments and Therapies to ESRD Recipients Kidney Care Act or the BETTER Kidney Care Act Final Rule for Medicare Advantage program requirements for contract years 2021 and 2022. COVID-19 emergency aid packages. S. 3548-Coronavirus Aid, Relief, and Economic Security Act & Consolidated Appropriations Act, 2021 (COVID relief package) Telehealth policies/CMS Waivers Medicare Physician Fee Schedule for 2021- payment cuts for specialty physicians. The Administrations CMMI Model for Kidney Disease - ESRD Treatment Choices Model & KCC Model Centers for Medicare & Medicaid Services (CMS) final Medicare Advantage (MA) and Part D rule ESRD Seamless Care Organizations (ESCO) Models COVID-19 Vaccine Distribution COVID-19 emergency aid packages Omnibus spending and COVID-19 relief bill

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Office of the Vice President of the United States; SENATE

Bills named: H.R. 8254 (116th), S. 3548 (116th), S. 4574 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.